Home/Filings/4/0001437749-21-017953
4//SEC Filing

Buckheit Robert 4

Accession 0001437749-21-017953

CIK 0001318641other

Filed

Jul 28, 8:00 PM ET

Accepted

Jul 29, 9:34 PM ET

Size

5.1 KB

Accession

0001437749-21-017953

Insider Transaction Report

Form 4
Period: 2021-07-27
Buckheit Robert
Chief Technology Officer
Transactions
  • Award

    Common Stock, par value $0.005 per share

    2021-07-27+24,37824,378 total
Footnotes (1)
  • [F1]Shares received pursuant to an Agreement and Plan of Merger ("merger agreement"), entered into by Cytocom Inc. ("Old Cytocom") and Cleveland BioLabs, Inc ("New Cytocom" or "Issuer"). Per the "merger agreement", each share of Old Cytocom (i) common stock, (ii) preferred stock that was not converted into Old Cytocom common stock immediately prior to the effective time of the Merger, and (iii) each vested restricted stock unit of Old Cytocom (excluding, in each case, dissenting shares and shares held in treasury) converted into the right to receive a number of shares of New Cytocom common stock based on an exchange formula set forth in the merger agreement (which we refer to as the "merger consideration").

Issuer

Cytocom, Inc.

CIK 0001318641

Entity typeother

Related Parties

1
  • filerCIK 0001871727

Filing Metadata

Form type
4
Filed
Jul 28, 8:00 PM ET
Accepted
Jul 29, 9:34 PM ET
Size
5.1 KB